X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30

$3.12−0.05 (-1.58%)

Close on Nov 13, 2026Market cap $309.34MP/E –Yield –

X4 Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

X4 Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in X4 Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Apr 28, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing